Illinois 2023-2024 Regular Session

Illinois House Bill HB4822 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB4822 Introduced 2/6/2024, by Rep. Natalie A. Manley SYNOPSIS AS INTRODUCED: 215 ILCS 5/356z.63225 ILCS 85/3 Amends the Pharmacy Practice Act and the Illinois Insurance Code. In the definition of "practice of pharmacy", includes the ordering of testing, screening, and treatment (rather than the ordering and administration of tests and screenings) for influenza. Makes conforming changes. Effective January 1, 2025. LRB103 37464 RTM 67587 b A BILL FOR 103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB4822 Introduced 2/6/2024, by Rep. Natalie A. Manley SYNOPSIS AS INTRODUCED: 215 ILCS 5/356z.63225 ILCS 85/3 215 ILCS 5/356z.63 225 ILCS 85/3 Amends the Pharmacy Practice Act and the Illinois Insurance Code. In the definition of "practice of pharmacy", includes the ordering of testing, screening, and treatment (rather than the ordering and administration of tests and screenings) for influenza. Makes conforming changes. Effective January 1, 2025. LRB103 37464 RTM 67587 b LRB103 37464 RTM 67587 b A BILL FOR
2	2	103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB4822 Introduced 2/6/2024, by Rep. Natalie A. Manley SYNOPSIS AS INTRODUCED:
3	3	215 ILCS 5/356z.63225 ILCS 85/3 215 ILCS 5/356z.63 225 ILCS 85/3
4	4	215 ILCS 5/356z.63
5	5	225 ILCS 85/3
6	6	Amends the Pharmacy Practice Act and the Illinois Insurance Code. In the definition of "practice of pharmacy", includes the ordering of testing, screening, and treatment (rather than the ordering and administration of tests and screenings) for influenza. Makes conforming changes. Effective January 1, 2025.
7	7	LRB103 37464 RTM 67587 b LRB103 37464 RTM 67587 b
8	8	LRB103 37464 RTM 67587 b
9	9	A BILL FOR
10	10	HB4822LRB103 37464 RTM 67587 b HB4822 LRB103 37464 RTM 67587 b
11	11	HB4822 LRB103 37464 RTM 67587 b
12	12	1 AN ACT concerning regulation.
13	13	2 Be it enacted by the People of the State of Illinois,
14	14	3 represented in the General Assembly:
15	15	4 Section 5. The Illinois Insurance Code is amended by
16	16	5 changing Section 356z.63 as follows:
17	17	6 (215 ILCS 5/356z.63)
18	18	7 Sec. 356z.63 356z.61. Coverage of pharmacy testing,
19	19	8 screening, vaccinations, and treatment. A group or individual
20	20	9 policy of accident and health insurance or a managed care plan
21	21	10 that is amended, delivered, issued, or renewed on or after
22	22	11 January 1, 2025 shall provide coverage for health care or
23	23	12 patient care services provided by a pharmacist if:
24	24	13 (1) the pharmacist meets the requirements and scope of
25	25	14 practice described in paragraph (15), (16), or (17), or
26	26	15 (18) of subsection (d) of Section 3 of the Pharmacy
27	27	16 Practice Act;
28	28	17 (2) the health plan provides coverage for the same
29	29	18 service provided by a licensed physician, an advanced
30	30	19 practice registered nurse, or a physician assistant;
31	31	20 (3) the pharmacist is included in the health benefit
32	32	21 plan's network of participating providers; and
33	33	22 (4) reimbursement has been successfully negotiated in
34	34	23 good faith between the pharmacist and the health plan.
35	35
36	36
37	37
38	38	103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB4822 Introduced 2/6/2024, by Rep. Natalie A. Manley SYNOPSIS AS INTRODUCED:
39	39	215 ILCS 5/356z.63225 ILCS 85/3 215 ILCS 5/356z.63 225 ILCS 85/3
40	40	215 ILCS 5/356z.63
41	41	225 ILCS 85/3
42	42	Amends the Pharmacy Practice Act and the Illinois Insurance Code. In the definition of "practice of pharmacy", includes the ordering of testing, screening, and treatment (rather than the ordering and administration of tests and screenings) for influenza. Makes conforming changes. Effective January 1, 2025.
43	43	LRB103 37464 RTM 67587 b LRB103 37464 RTM 67587 b
44	44	LRB103 37464 RTM 67587 b
45	45	A BILL FOR
46	46
47	47
48	48
49	49
50	50
51	51	215 ILCS 5/356z.63
52	52	225 ILCS 85/3
53	53
54	54
55	55
56	56	LRB103 37464 RTM 67587 b
57	57
58	58
59	59
60	60
61	61
62	62
63	63
64	64
65	65
66	66	HB4822 LRB103 37464 RTM 67587 b
67	67
68	68
69	69	HB4822- 2 -LRB103 37464 RTM 67587 b HB4822 - 2 - LRB103 37464 RTM 67587 b
70	70	HB4822 - 2 - LRB103 37464 RTM 67587 b
71	71	1 (Source: P.A. 103-1, eff. 4-27-23; revised 8-29-23.)
72	72	2 Section 10. The Pharmacy Practice Act is amended by
73	73	3 changing Section 3 as follows:
74	74	4 (225 ILCS 85/3)
75	75	5 (Section scheduled to be repealed on January 1, 2028)
76	76	6 Sec. 3. Definitions. For the purpose of this Act, except
77	77	7 where otherwise limited therein:
78	78	8 (a) "Pharmacy" or "drugstore" means and includes every
79	79	9 store, shop, pharmacy department, or other place where
80	80	10 pharmacist care is provided by a pharmacist (1) where drugs,
81	81	11 medicines, or poisons are dispensed, sold or offered for sale
82	82	12 at retail, or displayed for sale at retail; or (2) where
83	83	13 prescriptions of physicians, dentists, advanced practice
84	84	14 registered nurses, physician assistants, veterinarians,
85	85	15 podiatric physicians, or optometrists, within the limits of
86	86	16 their licenses, are compounded, filled, or dispensed; or (3)
87	87	17 which has upon it or displayed within it, or affixed to or used
88	88	18 in connection with it, a sign bearing the word or words
89	89	19 "Pharmacist", "Druggist", "Pharmacy", "Pharmaceutical Care",
90	90	20 "Apothecary", "Drugstore", "Medicine Store", "Prescriptions",
91	91	21 "Drugs", "Dispensary", "Medicines", or any word or words of
92	92	22 similar or like import, either in the English language or any
93	93	23 other language; or (4) where the characteristic prescription
94	94	24 sign (Rx) or similar design is exhibited; or (5) any store, or
95	95
96	96
97	97
98	98
99	99
100	100	HB4822 - 2 - LRB103 37464 RTM 67587 b
101	101
102	102
103	103	HB4822- 3 -LRB103 37464 RTM 67587 b HB4822 - 3 - LRB103 37464 RTM 67587 b
104	104	HB4822 - 3 - LRB103 37464 RTM 67587 b
105	105	1 shop, or other place with respect to which any of the above
106	106	2 words, objects, signs or designs are used in any
107	107	3 advertisement.
108	108	4 (b) "Drugs" means and includes (1) articles recognized in
109	109	5 the official United States Pharmacopoeia/National Formulary
110	110	6 (USP/NF), or any supplement thereto and being intended for and
111	111	7 having for their main use the diagnosis, cure, mitigation,
112	112	8 treatment or prevention of disease in man or other animals, as
113	113	9 approved by the United States Food and Drug Administration,
114	114	10 but does not include devices or their components, parts, or
115	115	11 accessories; and (2) all other articles intended for and
116	116	12 having for their main use the diagnosis, cure, mitigation,
117	117	13 treatment or prevention of disease in man or other animals, as
118	118	14 approved by the United States Food and Drug Administration,
119	119	15 but does not include devices or their components, parts, or
120	120	16 accessories; and (3) articles (other than food) having for
121	121	17 their main use and intended to affect the structure or any
122	122	18 function of the body of man or other animals; and (4) articles
123	123	19 having for their main use and intended for use as a component
124	124	20 or any articles specified in clause (1), (2) or (3); but does
125	125	21 not include devices or their components, parts or accessories.
126	126	22 (c) "Medicines" means and includes all drugs intended for
127	127	23 human or veterinary use approved by the United States Food and
128	128	24 Drug Administration.
129	129	25 (d) "Practice of pharmacy" means:
130	130	26 (1) the interpretation and the provision of assistance
131	131
132	132
133	133
134	134
135	135
136	136	HB4822 - 3 - LRB103 37464 RTM 67587 b
137	137
138	138
139	139	HB4822- 4 -LRB103 37464 RTM 67587 b HB4822 - 4 - LRB103 37464 RTM 67587 b
140	140	HB4822 - 4 - LRB103 37464 RTM 67587 b
141	141	1 in the monitoring, evaluation, and implementation of
142	142	2 prescription drug orders;
143	143	3 (2) the dispensing of prescription drug orders;
144	144	4 (3) participation in drug and device selection;
145	145	5 (4) drug administration limited to the administration
146	146	6 of oral, topical, injectable, and inhalation as follows:
147	147	7 (A) in the context of patient education on the
148	148	8 proper use or delivery of medications;
149	149	9 (B) vaccination of patients 7 years of age and
150	150	10 older pursuant to a valid prescription or standing
151	151	11 order, by a physician licensed to practice medicine in
152	152	12 all its branches, except for vaccinations covered by
153	153	13 paragraph (15), upon completion of appropriate
154	154	14 training, including how to address contraindications
155	155	15 and adverse reactions set forth by rule, with
156	156	16 notification to the patient's physician and
157	157	17 appropriate record retention, or pursuant to hospital
158	158	18 pharmacy and therapeutics committee policies and
159	159	19 procedures. Eligible vaccines are those listed on the
160	160	20 U.S. Centers for Disease Control and Prevention (CDC)
161	161	21 Recommended Immunization Schedule, the CDC's Health
162	162	22 Information for International Travel, or the U.S. Food
163	163	23 and Drug Administration's Vaccines Licensed and
164	164	24 Authorized for Use in the United States. As applicable
165	165	25 to the State's Medicaid program and other payers,
166	166	26 vaccines ordered and administered in accordance with
167	167
168	168
169	169
170	170
171	171
172	172	HB4822 - 4 - LRB103 37464 RTM 67587 b
173	173
174	174
175	175	HB4822- 5 -LRB103 37464 RTM 67587 b HB4822 - 5 - LRB103 37464 RTM 67587 b
176	176	HB4822 - 5 - LRB103 37464 RTM 67587 b
177	177	1 this subsection shall be covered and reimbursed at no
178	178	2 less than the rate that the vaccine is reimbursed when
179	179	3 ordered and administered by a physician;
180	180	4 (B-5) following the initial administration of
181	181	5 long-acting or extended-release form opioid
182	182	6 antagonists by a physician licensed to practice
183	183	7 medicine in all its branches, administration of
184	184	8 injections of long-acting or extended-release form
185	185	9 opioid antagonists for the treatment of substance use
186	186	10 disorder, pursuant to a valid prescription by a
187	187	11 physician licensed to practice medicine in all its
188	188	12 branches, upon completion of appropriate training,
189	189	13 including how to address contraindications and adverse
190	190	14 reactions, including, but not limited to, respiratory
191	191	15 depression and the performance of cardiopulmonary
192	192	16 resuscitation, set forth by rule, with notification to
193	193	17 the patient's physician and appropriate record
194	194	18 retention, or pursuant to hospital pharmacy and
195	195	19 therapeutics committee policies and procedures;
196	196	20 (C) administration of injections of
197	197	21 alpha-hydroxyprogesterone caproate, pursuant to a
198	198	22 valid prescription, by a physician licensed to
199	199	23 practice medicine in all its branches, upon completion
200	200	24 of appropriate training, including how to address
201	201	25 contraindications and adverse reactions set forth by
202	202	26 rule, with notification to the patient's physician and
203	203
204	204
205	205
206	206
207	207
208	208	HB4822 - 5 - LRB103 37464 RTM 67587 b
209	209
210	210
211	211	HB4822- 6 -LRB103 37464 RTM 67587 b HB4822 - 6 - LRB103 37464 RTM 67587 b
212	212	HB4822 - 6 - LRB103 37464 RTM 67587 b
213	213	1 appropriate record retention, or pursuant to hospital
214	214	2 pharmacy and therapeutics committee policies and
215	215	3 procedures; and
216	216	4 (D) administration of injections of long-term
217	217	5 antipsychotic medications pursuant to a valid
218	218	6 prescription by a physician licensed to practice
219	219	7 medicine in all its branches, upon completion of
220	220	8 appropriate training conducted by an Accreditation
221	221	9 Council of Pharmaceutical Education accredited
222	222	10 provider, including how to address contraindications
223	223	11 and adverse reactions set forth by rule, with
224	224	12 notification to the patient's physician and
225	225	13 appropriate record retention, or pursuant to hospital
226	226	14 pharmacy and therapeutics committee policies and
227	227	15 procedures.
228	228	16 (5) (blank);
229	229	17 (6) drug regimen review;
230	230	18 (7) drug or drug-related research;
231	231	19 (8) the provision of patient counseling;
232	232	20 (9) the practice of telepharmacy;
233	233	21 (10) the provision of those acts or services necessary
234	234	22 to provide pharmacist care;
235	235	23 (11) medication therapy management;
236	236	24 (12) the responsibility for compounding and labeling
237	237	25 of drugs and devices (except labeling by a manufacturer,
238	238	26 repackager, or distributor of non-prescription drugs and
239	239
240	240
241	241
242	242
243	243
244	244	HB4822 - 6 - LRB103 37464 RTM 67587 b
245	245
246	246
247	247	HB4822- 7 -LRB103 37464 RTM 67587 b HB4822 - 7 - LRB103 37464 RTM 67587 b
248	248	HB4822 - 7 - LRB103 37464 RTM 67587 b
249	249	1 commercially packaged legend drugs and devices), proper
250	250	2 and safe storage of drugs and devices, and maintenance of
251	251	3 required records;
252	252	4 (13) the assessment and consultation of patients and
253	253	5 dispensing of hormonal contraceptives;
254	254	6 (14) the initiation, dispensing, or administration of
255	255	7 drugs, laboratory tests, assessments, referrals, and
256	256	8 consultations for human immunodeficiency virus
257	257	9 pre-exposure prophylaxis and human immunodeficiency virus
258	258	10 post-exposure prophylaxis under Section 43.5;
259	259	11 (15) vaccination of patients 7 years of age and older
260	260	12 for COVID-19 or influenza subcutaneously, intramuscularly,
261	261	13 or orally as authorized, approved, or licensed by the
262	262	14 United States Food and Drug Administration, pursuant to
263	263	15 the following conditions:
264	264	16 (A) the vaccine must be authorized or licensed by
265	265	17 the United States Food and Drug Administration;
266	266	18 (B) the vaccine must be ordered and administered
267	267	19 according to the Advisory Committee on Immunization
268	268	20 Practices standard immunization schedule;
269	269	21 (C) the pharmacist must complete a course of
270	270	22 training accredited by the Accreditation Council on
271	271	23 Pharmacy Education or a similar health authority or
272	272	24 professional body approved by the Division of
273	273	25 Professional Regulation;
274	274	26 (D) the pharmacist must have a current certificate
275	275
276	276
277	277
278	278
279	279
280	280	HB4822 - 7 - LRB103 37464 RTM 67587 b
281	281
282	282
283	283	HB4822- 8 -LRB103 37464 RTM 67587 b HB4822 - 8 - LRB103 37464 RTM 67587 b
284	284	HB4822 - 8 - LRB103 37464 RTM 67587 b
285	285	1 in basic cardiopulmonary resuscitation;
286	286	2 (E) the pharmacist must complete, during each
287	287	3 State licensing period, a minimum of 2 hours of
288	288	4 immunization-related continuing pharmacy education
289	289	5 approved by the Accreditation Council on Pharmacy
290	290	6 Education;
291	291	7 (F) the pharmacist must comply with recordkeeping
292	292	8 and reporting requirements of the jurisdiction in
293	293	9 which the pharmacist administers vaccines, including
294	294	10 informing the patient's primary-care provider, when
295	295	11 available, and complying with requirements whereby the
296	296	12 person administering a vaccine must review the vaccine
297	297	13 registry or other vaccination records prior to
298	298	14 administering the vaccine; and
299	299	15 (G) the pharmacist must inform the pharmacist's
300	300	16 patients who are less than 18 years old, as well as the
301	301	17 adult caregiver accompanying the child, of the
302	302	18 importance of a well-child visit with a pediatrician
303	303	19 or other licensed primary-care provider and must refer
304	304	20 patients as appropriate;
305	305	21 (16) the ordering and administration of COVID-19
306	306	22 therapeutics subcutaneously, intramuscularly, or orally
307	307	23 with notification to the patient's physician and
308	308	24 appropriate record retention or pursuant to hospital
309	309	25 pharmacy and therapeutics committee policies and
310	310	26 procedures. Eligible therapeutics are those approved,
311	311
312	312
313	313
314	314
315	315
316	316	HB4822 - 8 - LRB103 37464 RTM 67587 b
317	317
318	318
319	319	HB4822- 9 -LRB103 37464 RTM 67587 b HB4822 - 9 - LRB103 37464 RTM 67587 b
320	320	HB4822 - 9 - LRB103 37464 RTM 67587 b
321	321	1 authorized, or licensed by the United States Food and Drug
322	322	2 Administration and must be administered subcutaneously,
323	323	3 intramuscularly, or orally in accordance with that
324	324	4 approval, authorization, or licensing; and
325	325	5 (17) the ordering and administration of tests and
326	326	6 screenings for SARS-CoV-2
327	327	(i) influenza, (ii) SARS-COV 2,
328	328	7 and (iii) health conditions identified by a statewide
329	329	8 public health emergency, as defined in the Illinois
330	330	9 Emergency Management Agency Act, with notification to the
331	331	10 patient's physician and appropriate record retention or
332	332	11 pursuant to hospital pharmacy and therapeutics committee
333	333	12 policies and procedures. Eligible tests and screenings are
334	334	13 those approved, authorized, or licensed by the United
335	335	14 States Food and Drug Administration and must be
336	336	15 administered in accordance with that approval,
337	337	16 authorization, or licensing; and .
338	338	17 (18) the ordering of testing, screening, and treatment
339	339	18 for influenza.
340	340	19 A pharmacist who orders testing, screening, or treatments
341	341	20 or administers tests or screenings for health conditions
342	342	21 described in paragraphs (17) and (18) this paragraph may use a
343	343	22 test that may guide clinical decision-making for the health
344	344	23 condition that is waived under the federal Clinical Laboratory
345	345	24 Improvement Amendments of 1988 and regulations promulgated
346	346	25 thereunder or any established screening procedure that is
347	347	26 established under a statewide protocol.
348	348
349	349
350	350
351	351
352	352
353	353	HB4822 - 9 - LRB103 37464 RTM 67587 b
354	354
355	355
356	356	HB4822- 10 -LRB103 37464 RTM 67587 b HB4822 - 10 - LRB103 37464 RTM 67587 b
357	357	HB4822 - 10 - LRB103 37464 RTM 67587 b
358	358	1 A pharmacist may delegate the administrative and technical
359	359	2 tasks of performing a test for the health conditions described
360	360	3 in paragraphs (17) and (18) this paragraph to a registered
361	361	4 pharmacy technician or student pharmacist acting under the
362	362	5 supervision of the pharmacist.
363	363	6 A pharmacist who performs any of the acts defined as the
364	364	7 practice of pharmacy in this State must be actively licensed
365	365	8 as a pharmacist under this Act.
366	366	9 (e) "Prescription" means and includes any written, oral,
367	367	10 facsimile, or electronically transmitted order for drugs or
368	368	11 medical devices, issued by a physician licensed to practice
369	369	12 medicine in all its branches, dentist, veterinarian, podiatric
370	370	13 physician, or optometrist, within the limits of his or her
371	371	14 license, by a physician assistant in accordance with
372	372	15 subsection (f) of Section 4, or by an advanced practice
373	373	16 registered nurse in accordance with subsection (g) of Section
374	374	17 4, containing the following: (1) name of the patient; (2) date
375	375	18 when prescription was issued; (3) name and strength of drug or
376	376	19 description of the medical device prescribed; and (4)
377	377	20 quantity; (5) directions for use; (6) prescriber's name,
378	378	21 address, and signature; and (7) DEA registration number where
379	379	22 required, for controlled substances. The prescription may, but
380	380	23 is not required to, list the illness, disease, or condition
381	381	24 for which the drug or device is being prescribed. DEA
382	382	25 registration numbers shall not be required on inpatient drug
383	383	26 orders. A prescription for medication other than controlled
384	384
385	385
386	386
387	387
388	388
389	389	HB4822 - 10 - LRB103 37464 RTM 67587 b
390	390
391	391
392	392	HB4822- 11 -LRB103 37464 RTM 67587 b HB4822 - 11 - LRB103 37464 RTM 67587 b
393	393	HB4822 - 11 - LRB103 37464 RTM 67587 b
394	394	1 substances shall be valid for up to 15 months from the date
395	395	2 issued for the purpose of refills, unless the prescription
396	396	3 states otherwise.
397	397	4 (f) "Person" means and includes a natural person,
398	398	5 partnership, association, corporation, government entity, or
399	399	6 any other legal entity.
400	400	7 (g) "Department" means the Department of Financial and
401	401	8 Professional Regulation.
402	402	9 (h) "Board of Pharmacy" or "Board" means the State Board
403	403	10 of Pharmacy of the Department of Financial and Professional
404	404	11 Regulation.
405	405	12 (i) "Secretary" means the Secretary of Financial and
406	406	13 Professional Regulation.
407	407	14 (j) "Drug product selection" means the interchange for a
408	408	15 prescribed pharmaceutical product in accordance with Section
409	409	16 25 of this Act and Section 3.14 of the Illinois Food, Drug and
410	410	17 Cosmetic Act.
411	411	18 (k) "Inpatient drug order" means an order issued by an
412	412	19 authorized prescriber for a resident or patient of a facility
413	413	20 licensed under the Nursing Home Care Act, the ID/DD Community
414	414	21 Care Act, the MC/DD Act, the Specialized Mental Health
415	415	22 Rehabilitation Act of 2013, the Hospital Licensing Act, or the
416	416	23 University of Illinois Hospital Act, or a facility which is
417	417	24 operated by the Department of Human Services (as successor to
418	418	25 the Department of Mental Health and Developmental
419	419	26 Disabilities) or the Department of Corrections.
420	420
421	421
422	422
423	423
424	424
425	425	HB4822 - 11 - LRB103 37464 RTM 67587 b
426	426
427	427
428	428	HB4822- 12 -LRB103 37464 RTM 67587 b HB4822 - 12 - LRB103 37464 RTM 67587 b
429	429	HB4822 - 12 - LRB103 37464 RTM 67587 b
430	430	1 (k-5) "Pharmacist" means an individual health care
431	431	2 professional and provider currently licensed by this State to
432	432	3 engage in the practice of pharmacy.
433	433	4 (l) "Pharmacist in charge" means the licensed pharmacist
434	434	5 whose name appears on a pharmacy license and who is
435	435	6 responsible for all aspects of the operation related to the
436	436	7 practice of pharmacy.
437	437	8 (m) "Dispense" or "dispensing" means the interpretation,
438	438	9 evaluation, and implementation of a prescription drug order,
439	439	10 including the preparation and delivery of a drug or device to a
440	440	11 patient or patient's agent in a suitable container
441	441	12 appropriately labeled for subsequent administration to or use
442	442	13 by a patient in accordance with applicable State and federal
443	443	14 laws and regulations. "Dispense" or "dispensing" does not mean
444	444	15 the physical delivery to a patient or a patient's
445	445	16 representative in a home or institution by a designee of a
446	446	17 pharmacist or by common carrier. "Dispense" or "dispensing"
447	447	18 also does not mean the physical delivery of a drug or medical
448	448	19 device to a patient or patient's representative by a
449	449	20 pharmacist's designee within a pharmacy or drugstore while the
450	450	21 pharmacist is on duty and the pharmacy is open.
451	451	22 (n) "Nonresident pharmacy" means a pharmacy that is
452	452	23 located in a state, commonwealth, or territory of the United
453	453	24 States, other than Illinois, that delivers, dispenses, or
454	454	25 distributes, through the United States Postal Service,
455	455	26 commercially acceptable parcel delivery service, or other
456	456
457	457
458	458
459	459
460	460
461	461	HB4822 - 12 - LRB103 37464 RTM 67587 b
462	462
463	463
464	464	HB4822- 13 -LRB103 37464 RTM 67587 b HB4822 - 13 - LRB103 37464 RTM 67587 b
465	465	HB4822 - 13 - LRB103 37464 RTM 67587 b
466	466	1 common carrier, to Illinois residents, any substance which
467	467	2 requires a prescription.
468	468	3 (o) "Compounding" means the preparation and mixing of
469	469	4 components, excluding flavorings, (1) as the result of a
470	470	5 prescriber's prescription drug order or initiative based on
471	471	6 the prescriber-patient-pharmacist relationship in the course
472	472	7 of professional practice or (2) for the purpose of, or
473	473	8 incident to, research, teaching, or chemical analysis and not
474	474	9 for sale or dispensing. "Compounding" includes the preparation
475	475	10 of drugs or devices in anticipation of receiving prescription
476	476	11 drug orders based on routine, regularly observed dispensing
477	477	12 patterns. Commercially available products may be compounded
478	478	13 for dispensing to individual patients only if all of the
479	479	14 following conditions are met: (i) the commercial product is
480	480	15 not reasonably available from normal distribution channels in
481	481	16 a timely manner to meet the patient's needs and (ii) the
482	482	17 prescribing practitioner has requested that the drug be
483	483	18 compounded.
484	484	19 (p) (Blank).
485	485	20 (q) (Blank).
486	486	21 (r) "Patient counseling" means the communication between a
487	487	22 pharmacist or a student pharmacist under the supervision of a
488	488	23 pharmacist and a patient or the patient's representative about
489	489	24 the patient's medication or device for the purpose of
490	490	25 optimizing proper use of prescription medications or devices.
491	491	26 "Patient counseling" may include without limitation (1)
492	492
493	493
494	494
495	495
496	496
497	497	HB4822 - 13 - LRB103 37464 RTM 67587 b
498	498
499	499
500	500	HB4822- 14 -LRB103 37464 RTM 67587 b HB4822 - 14 - LRB103 37464 RTM 67587 b
501	501	HB4822 - 14 - LRB103 37464 RTM 67587 b
502	502	1 obtaining a medication history; (2) acquiring a patient's
503	503	2 allergies and health conditions; (3) facilitation of the
504	504	3 patient's understanding of the intended use of the medication;
505	505	4 (4) proper directions for use; (5) significant potential
506	506	5 adverse events; (6) potential food-drug interactions; and (7)
507	507	6 the need to be compliant with the medication therapy. A
508	508	7 pharmacy technician may only participate in the following
509	509	8 aspects of patient counseling under the supervision of a
510	510	9 pharmacist: (1) obtaining medication history; (2) providing
511	511	10 the offer for counseling by a pharmacist or student
512	512	11 pharmacist; and (3) acquiring a patient's allergies and health
513	513	12 conditions.
514	514	13 (s) "Patient profiles" or "patient drug therapy record"
515	515	14 means the obtaining, recording, and maintenance of patient
516	516	15 prescription information, including prescriptions for
517	517	16 controlled substances, and personal information.
518	518	17 (t) (Blank).
519	519	18 (u) "Medical device" or "device" means an instrument,
520	520	19 apparatus, implement, machine, contrivance, implant, in vitro
521	521	20 reagent, or other similar or related article, including any
522	522	21 component part or accessory, required under federal law to
523	523	22 bear the label "Caution: Federal law requires dispensing by or
524	524	23 on the order of a physician". A seller of goods and services
525	525	24 who, only for the purpose of retail sales, compounds, sells,
526	526	25 rents, or leases medical devices shall not, by reasons
527	527	26 thereof, be required to be a licensed pharmacy.
528	528
529	529
530	530
531	531
532	532
533	533	HB4822 - 14 - LRB103 37464 RTM 67587 b
534	534
535	535
536	536	HB4822- 15 -LRB103 37464 RTM 67587 b HB4822 - 15 - LRB103 37464 RTM 67587 b
537	537	HB4822 - 15 - LRB103 37464 RTM 67587 b
538	538	1 (v) "Unique identifier" means an electronic signature,
539	539	2 handwritten signature or initials, thumb print, or other
540	540	3 acceptable biometric or electronic identification process as
541	541	4 approved by the Department.
542	542	5 (w) "Current usual and customary retail price" means the
543	543	6 price that a pharmacy charges to a non-third-party payor.
544	544	7 (x) "Automated pharmacy system" means a mechanical system
545	545	8 located within the confines of the pharmacy or remote location
546	546	9 that performs operations or activities, other than compounding
547	547	10 or administration, relative to storage, packaging, dispensing,
548	548	11 or distribution of medication, and which collects, controls,
549	549	12 and maintains all transaction information.
550	550	13 (y) "Drug regimen review" means and includes the
551	551	14 evaluation of prescription drug orders and patient records for
552	552	15 (1) known allergies; (2) drug or potential therapy
553	553	16 contraindications; (3) reasonable dose, duration of use, and
554	554	17 route of administration, taking into consideration factors
555	555	18 such as age, gender, and contraindications; (4) reasonable
556	556	19 directions for use; (5) potential or actual adverse drug
557	557	20 reactions; (6) drug-drug interactions; (7) drug-food
558	558	21 interactions; (8) drug-disease contraindications; (9)
559	559	22 therapeutic duplication; (10) patient laboratory values when
560	560	23 authorized and available; (11) proper utilization (including
561	561	24 over or under utilization) and optimum therapeutic outcomes;
562	562	25 and (12) abuse and misuse.
563	563	26 (z) "Electronically transmitted prescription" means a
564	564
565	565
566	566
567	567
568	568
569	569	HB4822 - 15 - LRB103 37464 RTM 67587 b
570	570
571	571
572	572	HB4822- 16 -LRB103 37464 RTM 67587 b HB4822 - 16 - LRB103 37464 RTM 67587 b
573	573	HB4822 - 16 - LRB103 37464 RTM 67587 b
574	574	1 prescription that is created, recorded, or stored by
575	575	2 electronic means; issued and validated with an electronic
576	576	3 signature; and transmitted by electronic means directly from
577	577	4 the prescriber to a pharmacy. An electronic prescription is
578	578	5 not an image of a physical prescription that is transferred by
579	579	6 electronic means from computer to computer, facsimile to
580	580	7 facsimile, or facsimile to computer.
581	581	8 (aa) "Medication therapy management services" means a
582	582	9 distinct service or group of services offered by licensed
583	583	10 pharmacists, physicians licensed to practice medicine in all
584	584	11 its branches, advanced practice registered nurses authorized
585	585	12 in a written agreement with a physician licensed to practice
586	586	13 medicine in all its branches, or physician assistants
587	587	14 authorized in guidelines by a supervising physician that
588	588	15 optimize therapeutic outcomes for individual patients through
589	589	16 improved medication use. In a retail or other non-hospital
590	590	17 pharmacy, medication therapy management services shall consist
591	591	18 of the evaluation of prescription drug orders and patient
592	592	19 medication records to resolve conflicts with the following:
593	593	20 (1) known allergies;
594	594	21 (2) drug or potential therapy contraindications;
595	595	22 (3) reasonable dose, duration of use, and route of
596	596	23 administration, taking into consideration factors such as
597	597	24 age, gender, and contraindications;
598	598	25 (4) reasonable directions for use;
599	599	26 (5) potential or actual adverse drug reactions;
600	600
601	601
602	602
603	603
604	604
605	605	HB4822 - 16 - LRB103 37464 RTM 67587 b
606	606
607	607
608	608	HB4822- 17 -LRB103 37464 RTM 67587 b HB4822 - 17 - LRB103 37464 RTM 67587 b
609	609	HB4822 - 17 - LRB103 37464 RTM 67587 b
610	610	1 (6) drug-drug interactions;
611	611	2 (7) drug-food interactions;
612	612	3 (8) drug-disease contraindications;
613	613	4 (9) identification of therapeutic duplication;
614	614	5 (10) patient laboratory values when authorized and
615	615	6 available;
616	616	7 (11) proper utilization (including over or under
617	617	8 utilization) and optimum therapeutic outcomes; and
618	618	9 (12) drug abuse and misuse.
619	619	10 "Medication therapy management services" includes the
620	620	11 following:
621	621	12 (1) documenting the services delivered and
622	622	13 communicating the information provided to patients'
623	623	14 prescribers within an appropriate time frame, not to
624	624	15 exceed 48 hours;
625	625	16 (2) providing patient counseling designed to enhance a
626	626	17 patient's understanding and the appropriate use of his or
627	627	18 her medications; and
628	628	19 (3) providing information, support services, and
629	629	20 resources designed to enhance a patient's adherence with
630	630	21 his or her prescribed therapeutic regimens.
631	631	22 "Medication therapy management services" may also include
632	632	23 patient care functions authorized by a physician licensed to
633	633	24 practice medicine in all its branches for his or her
634	634	25 identified patient or groups of patients under specified
635	635	26 conditions or limitations in a standing order from the
636	636
637	637
638	638
639	639
640	640
641	641	HB4822 - 17 - LRB103 37464 RTM 67587 b
642	642
643	643
644	644	HB4822- 18 -LRB103 37464 RTM 67587 b HB4822 - 18 - LRB103 37464 RTM 67587 b
645	645	HB4822 - 18 - LRB103 37464 RTM 67587 b
646	646	1 physician.
647	647	2 "Medication therapy management services" in a licensed
648	648	3 hospital may also include the following:
649	649	4 (1) reviewing assessments of the patient's health
650	650	5 status; and
651	651	6 (2) following protocols of a hospital pharmacy and
652	652	7 therapeutics committee with respect to the fulfillment of
653	653	8 medication orders.
654	654	9 (bb) "Pharmacist care" means the provision by a pharmacist
655	655	10 of medication therapy management services, with or without the
656	656	11 dispensing of drugs or devices, intended to achieve outcomes
657	657	12 that improve patient health, quality of life, and comfort and
658	658	13 enhance patient safety.
659	659	14 (cc) "Protected health information" means individually
660	660	15 identifiable health information that, except as otherwise
661	661	16 provided, is:
662	662	17 (1) transmitted by electronic media;
663	663	18 (2) maintained in any medium set forth in the
664	664	19 definition of "electronic media" in the federal Health
665	665	20 Insurance Portability and Accountability Act; or
666	666	21 (3) transmitted or maintained in any other form or
667	667	22 medium.
668	668	23 "Protected health information" does not include
669	669	24 individually identifiable health information found in:
670	670	25 (1) education records covered by the federal Family
671	671	26 Educational Right and Privacy Act; or
672	672
673	673
674	674
675	675
676	676
677	677	HB4822 - 18 - LRB103 37464 RTM 67587 b
678	678
679	679
680	680	HB4822- 19 -LRB103 37464 RTM 67587 b HB4822 - 19 - LRB103 37464 RTM 67587 b
681	681	HB4822 - 19 - LRB103 37464 RTM 67587 b
682	682	1 (2) employment records held by a licensee in its role
683	683	2 as an employer.
684	684	3 (dd) "Standing order" means a specific order for a patient
685	685	4 or group of patients issued by a physician licensed to
686	686	5 practice medicine in all its branches in Illinois.
687	687	6 (ee) "Address of record" means the designated address
688	688	7 recorded by the Department in the applicant's application file
689	689	8 or licensee's license file maintained by the Department's
690	690	9 licensure maintenance unit.
691	691	10 (ff) "Home pharmacy" means the location of a pharmacy's
692	692	11 primary operations.
693	693	12 (gg) "Email address of record" means the designated email
694	694	13 address recorded by the Department in the applicant's
695	695	14 application file or the licensee's license file, as maintained
696	696	15 by the Department's licensure maintenance unit.
697	697	16 (Source: P.A. 102-16, eff. 6-17-21; 102-103, eff. 1-1-22;
698	698	17 102-558, eff. 8-20-21; 102-813, eff. 5-13-22; 102-1051, eff.
699	699	18 1-1-23; 103-1, eff. 4-27-23.)
700	700
701	701
702	702
703	703
704	704
705	705	HB4822 - 19 - LRB103 37464 RTM 67587 b